{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:13:40Z","timestamp":1778523220164,"version":"3.51.4"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Appl Genetics"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Hemophilia B is a disease that affects the human coagulation system, causing the absence or deficiency of coagulation factor IX, which may manifest itself in uncontrolled bleeding that is life-threatening to patients. Due to its inheritance, the disease more often affects men, and the severity of symptoms directly correlates with the concentration of the missing factor IX; hence, the aim of therapy is to maintain it at a level that allows for sufficient hemostasis. The basic model of treatment offered to patients is based on primary prevention with coagulation factor IX with a prolonged half-life, which, however, does not solve the numerous problems faced by patients. An innovative proposal that, despite initial concerns, is becoming more and more popular every day is the recently approved genetic therapy in Europe, which uses viral vectors to transfer the correct gene that encodes coagulation factor IX. The introduction of a recombinant gene in place of its defective counterpart seems to be a promising solution and the beginning of a new era in which genetic therapies have a chance to develop their full potential and replace existing therapeutic regimens.<\/jats:p>","DOI":"10.1007\/s13353-025-00952-w","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T12:58:03Z","timestamp":1743771483000},"page":"569-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gene therapy as an innovative approach to the treatment of hemophilia B\u2014a review"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8740-9401","authenticated-orcid":false,"given":"Kinga","family":"Wr\u00f3blewska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1475-617X","authenticated-orcid":false,"given":"Dominika","family":"Bieszczad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0043-780X","authenticated-orcid":false,"given":"Magdalena","family":"Pop\u0142awska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6754-9263","authenticated-orcid":false,"given":"Karolina Joanna","family":"Zi\u0119tara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6545-4546","authenticated-orcid":false,"given":"Monika","family":"Zaj\u0105czkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7591-5887","authenticated-orcid":false,"given":"Agata","family":"Filip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"6","key":"952_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2450\/2019.0211-19","volume":"17","author":"L Aledort","year":"2019","unstructured":"Aledort L, Mannucci PM, Schramm W et al (2019) Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus 17(6):479\u2013486. https:\/\/doi.org\/10.2450\/2019.0211-19","journal-title":"Blood Transfus"},{"issue":"7","key":"952_CR2","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1182\/bloodadvances.2023010511","volume":"8","author":"XM Anguela","year":"2024","unstructured":"Anguela XM, High KA (2024) Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec. Blood Adv. 8(7):1796\u20131803. https:\/\/doi.org\/10.1182\/bloodadvances.2023010511","journal-title":"Blood Adv."},{"issue":"6","key":"952_CR3","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/jth.13331","volume":"14","author":"VR Arruda","year":"2016","unstructured":"Arruda VR, Samelson-Jones BJ (2016) Gene therapy for immune tolerance induction in hemophilia with inhibitors. J Thromb Haemost 14(6):1121\u20131134. https:\/\/doi.org\/10.1111\/jth.13331","journal-title":"J Thromb Haemost"},{"key":"952_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.809118","volume":"8","author":"HKE Au","year":"2022","unstructured":"Au HKE, Isalan M, Mielcarek M (2022) Gene therapy advances: a meta-analysis of AAV usage in clinical settings. Front Med 8:809118. https:\/\/doi.org\/10.3389\/fmed.2021.809118","journal-title":"Front Med"},{"issue":"1","key":"952_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-021-00285-y","volume":"7","author":"E Berntorp","year":"2021","unstructured":"Berntorp E, Fischer K, Hart DP et al (2021a) Haemophilia. Nat Rev Dis Primer 7(1):1\u201319. https:\/\/doi.org\/10.1038\/s41572-021-00285-y","journal-title":"Nat Rev Dis Primer"},{"key":"952_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100852","volume":"50","author":"E Berntorp","year":"2021","unstructured":"Berntorp E, Hermans C, Solms A, Poulsen L, Mancuso ME (2021b) Optimising prophylaxis in haemophilia A: the ups and downs of treatment. Blood Rev 50:100852. https:\/\/doi.org\/10.1016\/j.blre.2021.100852","journal-title":"Blood Rev"},{"issue":"6","key":"952_CR7","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","volume":"21","author":"S Boutin","year":"2010","unstructured":"Boutin S, Monteilhet V, Veron P et al (2010) Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 21(6):704\u2013712. https:\/\/doi.org\/10.1089\/hum.2009.182","journal-title":"Hum Gene Ther"},{"key":"952_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/JBM.S390521","volume":"14","author":"S Boyce","year":"2023","unstructured":"Boyce S, Rangarajan S (2023) RNAi for the treatment of people with hemophilia: current evidence and patient selection. J Blood Med 14:317\u2013327. https:\/\/doi.org\/10.2147\/JBM.S390521","journal-title":"J Blood Med"},{"issue":"4","key":"952_CR9","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/hae.13762","volume":"25","author":"M Carcao","year":"2019","unstructured":"Carcao M, Escuriola-Ettingshausen C, Santagostino E et al (2019) The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia 25(4):676\u2013684. https:\/\/doi.org\/10.1111\/hae.13762","journal-title":"Haemophilia"},{"issue":"12","key":"952_CR10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1080\/17474086.2023.2276206","volume":"16","author":"G Castaman","year":"2023","unstructured":"Castaman G, Coppens M, Pipe SW (2023) Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B. Expert Rev Hematol 16(12):919\u2013932. https:\/\/doi.org\/10.1080\/17474086.2023.2276206","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"952_CR11","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/blood-2014-07-588194","volume":"125","author":"JM Crudele","year":"2015","unstructured":"Crudele JM, Finn JD, Siner JI et al (2015) AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood 125(10):1553\u20131561. https:\/\/doi.org\/10.1182\/blood-2014-07-588194","journal-title":"Blood"},{"issue":"S3","key":"952_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/hae.14094","volume":"27","author":"R d\u2019Oiron","year":"2021","unstructured":"d\u2019Oiron R, O\u2019Brien S, James AH (2021) Women and girls with haemophilia: lessons learned. Haemophilia 27(S3):75\u201381. https:\/\/doi.org\/10.1111\/hae.14094","journal-title":"Haemophilia"},{"issue":"5","key":"952_CR13","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1073\/pnas.92.5.1401","volume":"92","author":"Y Dai","year":"1995","unstructured":"Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM (1995) Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A 92(5):1401\u20131405. https:\/\/doi.org\/10.1073\/pnas.92.5.1401","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"952_CR14","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.ymthe.2020.10.018","volume":"29","author":"DA Dalwadi","year":"2021","unstructured":"Dalwadi DA, Torrens L, Abril-Fornaguera J et al (2021) Liver injury increases the incidence of HCC following AAV gene therapy in mice. Mol Ther 29(2):680\u2013690. https:\/\/doi.org\/10.1016\/j.ymthe.2020.10.018","journal-title":"Mol Ther"},{"issue":"17\u201318","key":"952_CR15","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1089\/hum.2023.112","volume":"34","author":"D De Wolf","year":"2023","unstructured":"De Wolf D, Singh K, Chuah MK, VandenDriessche T (2023) Hemophilia gene therapy: the end of the beginning? Hum Gene Ther 34(17\u201318):782\u2013792. https:\/\/doi.org\/10.1089\/hum.2023.112","journal-title":"Hum Gene Ther"},{"issue":"5","key":"952_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1208\/s12248-023-00847-w","volume":"25","author":"J Donley","year":"2023","unstructured":"Donley J, Jani D, Zhu T, Xiang Y, Gorovits B, Arkin S (2023) Evolution of antidrug antibody assays during the development of anti-tissue factor pathway inhibitor monoclonal antibody marstacimab. AAPS J 25(5):84. https:\/\/doi.org\/10.1208\/s12248-023-00847-w","journal-title":"AAPS J"},{"key":"952_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.omtm.2020.11.015","volume":"20","author":"R Ferla","year":"2020","unstructured":"Ferla R, Alliegro M, Dell\u2019Anno M et al (2020) Low incidence of hepatocellular carcinoma in mice and cats treated with systemic adeno-associated viral vectors. Mol Ther Methods Clin Dev 20:247\u2013257. https:\/\/doi.org\/10.1016\/j.omtm.2020.11.015","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"23","key":"952_CR18","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1182\/blood-2012-06-440123","volume":"120","author":"JD Finn","year":"2012","unstructured":"Finn JD, Nichols TC, Svoronos N et al (2012) The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood 120(23):4521\u20134523. https:\/\/doi.org\/10.1182\/blood-2012-06-440123","journal-title":"Blood"},{"issue":"5","key":"952_CR19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1055\/s-0034-1381232","volume":"40","author":"M Franchini","year":"2014","unstructured":"Franchini M, Mannucci PM (2014) The history of hemophilia. Semin Thromb Hemost 40(5):571\u2013576. https:\/\/doi.org\/10.1055\/s-0034-1381232","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"952_CR20","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1055\/s-0042-1756188","volume":"48","author":"M Franchini","year":"2022","unstructured":"Franchini M, Mannucci PM (2022) The more recent history of hemophilia treatment. Semin Thromb Hemost 48(8):904\u2013910. https:\/\/doi.org\/10.1055\/s-0042-1756188","journal-title":"Semin Thromb Hemost"},{"key":"952_CR21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1182\/hematology.2021000254","volume":"1","author":"LA George","year":"2021","unstructured":"George LA (2021) (2021) Hemophilia gene therapy: ushering in a new treatment paradigm? Hematol Am Soc Hematol Educ Program 1:226\u2013233. https:\/\/doi.org\/10.1182\/hematology.2021000254","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"952_CR22","doi-asserted-by":"crossref","unstructured":"George LA, Sullivan SK, Adam G et al (2017) Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 377(23):2215\u20132227. https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1708538. Accessed 7 Dec 2017","DOI":"10.1056\/NEJMoa1708538"},{"issue":"9","key":"952_CR23","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","volume":"28","author":"LA George","year":"2020","unstructured":"George LA, Ragni MV, Rasko JEJ et al (2020) Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B. Mol Ther 28(9):2073\u20132082. https:\/\/doi.org\/10.1016\/j.ymthe.2020.06.001","journal-title":"Mol Ther"},{"issue":"13","key":"952_CR24","doi-asserted-by":"publisher","first-page":"204062072210852","DOI":"10.1177\/20406207221085202","volume":"2","author":"DP Hart","year":"2022","unstructured":"Hart DP, Matino D, Astermark J et al (2022) International consensus recommendations on the management of people with haemophilia B. Ther Adv Hematol 2(13):20406207221085200. https:\/\/doi.org\/10.1177\/20406207221085202","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"952_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40265-023-01845-0","volume":"83","author":"YA Heo","year":"2023","unstructured":"Heo YA (2023) Etranacogene dezaparvovec: first approval. Drugs 83(4):347\u2013352. https:\/\/doi.org\/10.1007\/s40265-023-01845-0","journal-title":"Drugs"},{"issue":"11","key":"952_CR26","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1073\/pnas.94.11.5804","volume":"94","author":"RW Herzog","year":"1997","unstructured":"Herzog RW, Hagstrom JN, Kung SH et al (1997) Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci 94(11):5804\u20135809. https:\/\/doi.org\/10.1073\/pnas.94.11.5804","journal-title":"Proc Natl Acad Sci"},{"key":"952_CR27","unstructured":"Hoffmann-La Roche Limited (2023) Product monograph including patient medication information Pr HEMLIBRA\u00ae emicizumab injection. F. Hoffmann-La Roche Ltd PhysicsWeb. https:\/\/assets.roche.com\/f\/173850\/x\/e0145f9e2a\/hemlibra_pm_e.pdf. Accessed 9 Mar 2023"},{"issue":"7","key":"952_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3097","volume":"21","author":"B Hu","year":"2019","unstructured":"Hu B, Weng Y, Xia XH, Liang XJ, Huang Y (2019) Clinical advances of siRNA therapeutics. J Gene Med 21(7):e3097. https:\/\/doi.org\/10.1002\/jgm.3097","journal-title":"J Gene Med"},{"key":"952_CR29","doi-asserted-by":"publisher","unstructured":"Hu Y, Li W (2022) Development and application of CRISPR-Cas based tools. Front Cell Dev Biol 10. https:\/\/doi.org\/10.3389\/fcell.2022.834646","DOI":"10.3389\/fcell.2022.834646"},{"issue":"24","key":"952_CR30","doi-asserted-by":"publisher","first-page":"9604","DOI":"10.3390\/ijms21249604","volume":"21","author":"E Janik","year":"2020","unstructured":"Janik E, Niemcewicz M, Ceremuga M, Krzowski L, Saluk-Bijak J, Bijak M (2020) Various aspects of a gene editing system-CRISPR-Cas9. Int J Mol Sci 21(24):9604. https:\/\/doi.org\/10.3390\/ijms21249604","journal-title":"Int J Mol Sci"},{"issue":"Suppl 3","key":"952_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/hae.14984","volume":"30","author":"R Kaczmarek","year":"2024","unstructured":"Kaczmarek R, Miesbach W, Ozelo MC et al (2024) Current and emerging gene therapies for haemophilia A and B. Haemophilia 30(Suppl 3):12\u201320. https:\/\/doi.org\/10.1111\/hae.14984","journal-title":"Haemophilia"},{"issue":"12","key":"952_CR32","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1016\/j.ymthe.2022.10.004","volume":"30","author":"A Kapelanski-Lamoureux","year":"2022","unstructured":"Kapelanski-Lamoureux A, Chen Z, Gao ZH et al (2022) Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma. Mol Ther. 30(12):3542\u20133551. https:\/\/doi.org\/10.1016\/j.ymthe.2022.10.004","journal-title":"Mol Ther."},{"issue":"5","key":"952_CR33","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1055\/s-2005-922221","volume":"31","author":"CK Kasper","year":"2005","unstructured":"Kasper CK (2005) Products for clotting factor replacement in developing countries. Semin Thromb Hemost 31(5):507\u2013512. https:\/\/doi.org\/10.1055\/s-2005-922221","journal-title":"Semin Thromb Hemost"},{"issue":"11","key":"952_CR34","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40265-023-01912-6","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023) Concizumab: first approval. Drugs 83(11):1053\u20131059. https:\/\/doi.org\/10.1007\/s40265-023-01912-6","journal-title":"Drugs"},{"issue":"22","key":"952_CR35","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1182\/blood.2023021864","volume":"143","author":"G Kenet","year":"2024","unstructured":"Kenet G, Nolan B, Zulfikar B et al (2024) Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA\/CFC prophylaxis: the ATLAS-PPX trial. Blood 143(22):2256\u20132269. https:\/\/doi.org\/10.1182\/blood.2023021864","journal-title":"Blood"},{"issue":"1","key":"952_CR36","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/blood-2003-10-3530","volume":"104","author":"DV Kravtsov","year":"2004","unstructured":"Kravtsov DV, Wu W, Meijers JC et al (2004) Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Blood 104(1):128\u201334. https:\/\/doi.org\/10.1182\/blood-2003-10-3530","journal-title":"Blood"},{"issue":"3","key":"952_CR37","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/rth2.12494","volume":"5","author":"E Krumb","year":"2021","unstructured":"Krumb E, Lambert C, Hermans C (2021) Patient selection for hemophilia gene therapy: real-life data from a single center. Res Pract Thromb Haemost. 5(3):390\u2013394. https:\/\/doi.org\/10.1002\/rth2.12494","journal-title":"Res Pract Thromb Haemost."},{"issue":"11","key":"952_CR38","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1182\/blood.2019003777","volume":"138","author":"FWG Leebeek","year":"2021","unstructured":"Leebeek FWG, Miesbach W (2021) Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues. Blood 138(11):923\u2013931. https:\/\/doi.org\/10.1182\/blood.2019003777","journal-title":"Blood"},{"issue":"6","key":"952_CR39","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.hoc.2021.07.012","volume":"35","author":"MD Lewandowska","year":"2021","unstructured":"Lewandowska MD, Connors JM (2021) Factor XI deficiency. Hematol Oncol Clin North Am 35(6):1157\u20131169. https:\/\/doi.org\/10.1016\/j.hoc.2021.07.012","journal-title":"Hematol Oncol Clin North Am"},{"key":"952_CR40","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.omtn.2021.03.022","volume":"24","author":"WY Lin","year":"2021","unstructured":"Lin WY, Zhu R, Zhang Z et al (2021) RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A. Mol Ther Nucleic Acids 24:658\u2013668. https:\/\/doi.org\/10.1016\/j.omtn.2021.03.022","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"952_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/ejh.13193","volume":"102","author":"R Ljung","year":"2019","unstructured":"Ljung R, Auerswald G, Benson G et al (2019) Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. Eur J Haematol 102(2):111\u2013122. https:\/\/doi.org\/10.1111\/ejh.13193","journal-title":"Eur J Haematol"},{"issue":"3","key":"952_CR42","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/mt.2016.10","volume":"24","author":"ML Maeder","year":"2016","unstructured":"Maeder ML, Gersbach CA (2016) Genome-editing technologies for gene and cell therapy. Mol Ther J Am Soc Gene Ther 24(3):430\u2013446. https:\/\/doi.org\/10.1038\/mt.2016.10","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"952_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","volume":"14","author":"A Majowicz","year":"2019","unstructured":"Majowicz A, Nijmeijer B, Lampen MH et al (2019) Therapeutic hFIX activity achieved after single AAV5-hFIX treatment in hemophilia B patients and NHPs with pre-existing anti-AAV5 NABs. Mol Ther Methods Clin Dev 14:27\u201336. https:\/\/doi.org\/10.1016\/j.omtm.2019.05.009","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"952_CR44","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno CS, Pierce GF, Arruda VR et al (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12(3):342\u2013347. https:\/\/doi.org\/10.1038\/nm1358","journal-title":"Nat Med"},{"issue":"1","key":"952_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-0038-1646153","volume":"70","author":"PM Mannucci","year":"1993","unstructured":"Mannucci PM (1993) Modern treatment of hemophilia: from the shadows towards the light. Thromb Haemost. 70(1):17\u201323","journal-title":"Thromb Haemost."},{"issue":"s3","key":"952_CR46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2516.2008.01708.x","volume":"14","author":"PM Mannucci","year":"2008","unstructured":"Mannucci PM (2008) Back to the future: a recent history of haemophilia treatment. Haemophilia 14(s3):10\u201318. https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01708.x","journal-title":"Haemophilia"},{"key":"952_CR47","doi-asserted-by":"crossref","unstructured":"Matsushita T, Shapiro A, Abraham A et al (2023) Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med. 389(9):783\u2013794. https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2216455. Accessed\u00a030 Aug\u00a0 2023","DOI":"10.1056\/NEJMoa2216455"},{"issue":"6","key":"952_CR48","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/hae.13845","volume":"25","author":"SL Meeks","year":"2019","unstructured":"Meeks SL, Leissinger CA (2019) The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors. Haemoph off J World Fed Hemoph 25(6):911\u2013918. https:\/\/doi.org\/10.1111\/hae.13845","journal-title":"Haemoph off J World Fed Hemoph"},{"issue":"1","key":"952_CR49","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1038\/s41467-022-30102-3","volume":"13","author":"M Milani","year":"2022","unstructured":"Milani M, Canepari C, Liu T et al (2022) Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates. Nat Commun 13(1):2454. https:\/\/doi.org\/10.1038\/s41467-022-30102-3","journal-title":"Nat Commun"},{"issue":"2","key":"952_CR50","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1111\/hae.14186","volume":"27","author":"CH Miller","year":"2021","unstructured":"Miller CH, Bean CJ (2021) Genetic causes of haemophilia in women and girls. Haemoph Off J World Fed Hemoph 27(2):e164\u2013e179. https:\/\/doi.org\/10.1111\/hae.14186","journal-title":"Haemoph Off J World Fed Hemoph"},{"key":"952_CR51","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.thromres.2020.12.033","volume":"236","author":"V Muczynski","year":"2024","unstructured":"Muczynski V, Nathwani AC (2024) AAV mediated gene therapy for haemophilia B: from the early attempts to modern trials. Thromb Res 236:242\u2013249. https:\/\/doi.org\/10.1016\/j.thromres.2020.12.033","journal-title":"Thromb Res"},{"issue":"1","key":"952_CR52","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1182\/hematology.2022000388","volume":"2022","author":"AC Nathwani","year":"2022","unstructured":"Nathwani AC (2022) Gene therapy for hemophilia. Hematol Am Soc Hematol Educ Program 2022(1):569\u2013578. https:\/\/doi.org\/10.1182\/hematology.2022000388","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"952_CR53","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12929-021-00760-4","volume":"28","author":"D Okaygoun","year":"2021","unstructured":"Okaygoun D, Oliveira DD, Soman S et al (2021) Advances in the management of haemophilia: emerging treatments and their mechanisms. J Biomed Sci 28(1):64. https:\/\/doi.org\/10.1186\/s12929-021-00760-4","journal-title":"J Biomed Sci"},{"issue":"3","key":"952_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12695","volume":"6","author":"MC Ozelo","year":"2022","unstructured":"Ozelo MC, Yamaguti-Hayakawa GG (2022) Impact of novel hemophilia therapies around the world. Res Pract Thromb Haemost 6(3):e12695. https:\/\/doi.org\/10.1002\/rth2.12695","journal-title":"Res Pract Thromb Haemost"},{"key":"952_CR55","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.thromres.2023.10.001","volume":"231","author":"JAD Pablo-Moreno","year":"2023","unstructured":"Pablo-Moreno JAD, Miguel-Batuecas A, Rodr\u00edguez-Merch\u00e1n EC, Liras A (2023) Treatment of congenital coagulopathies, from biologic to biotechnological drugs: the relevance of gene editing (CRISPR\/Cas). Thromb Res 231:99\u2013111. https:\/\/doi.org\/10.1016\/j.thromres.2023.10.001","journal-title":"Thromb Res"},{"key":"952_CR56","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/JBM.S242219","volume":"13","author":"S Pasca","year":"2022","unstructured":"Pasca S (2022) Concizumab as a subcutaneous prophylactic treatment option for patients with hemophilia A or B: a review of the evidence and patient\u2019s perspectives. J Blood Med 13:191\u2013199. https:\/\/doi.org\/10.2147\/JBM.S242219","journal-title":"J Blood Med"},{"issue":"6","key":"952_CR57","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/jth.15270","volume":"19","author":"KJ Pasi","year":"2021","unstructured":"Pasi KJ, Lissitchkov T, Mamonov V et al (2021) Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran\u2014results of the phase 1 inhibitor cohort. J Thromb Haemost 19(6):1436\u20131446. https:\/\/doi.org\/10.1111\/jth.15270","journal-title":"J Thromb Haemost"},{"key":"952_CR58","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.omtm.2020.06.003","volume":"18","author":"X Pei","year":"2010","unstructured":"Pei X, Shao W, Xing A et al (2010) Development of AAV variants with human hepatocyte tropism and neutralizing antibody escape capacity. Mol Ther Methods Clin Dev 18:259\u2013268. https:\/\/doi.org\/10.1016\/j.omtm.2020.06.003","journal-title":"Mol Ther Methods Clin Dev"},{"key":"952_CR59","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","volume":"388","author":"SW Pipe","year":"2023","unstructured":"Pipe SW, Leebeek FWG, Recht M et al (2023) Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med 388:706\u2013718. https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2211644.","journal-title":"N Engl J Med"},{"key":"952_CR60","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2020-138692","volume":"136","author":"RE Prince","year":"2020","unstructured":"Prince RE, Schaeper U, Dames S et al (2020) Targeting protein S using small interfering RNA is well tolerated and protects mice with hemophilia a from acute hemarthrosis. Blood 136:20\u201321. https:\/\/doi.org\/10.1182\/blood-2020-138692","journal-title":"Blood"},{"issue":"8","key":"952_CR61","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","volume":"30","author":"DE Sabatino","year":"2022","unstructured":"Sabatino DE, Bushman FD, Chandler RJ et al (2022) Evaluating the state of the science for adeno-associated virus integration: an integrated perspective. Mol Ther 30(8):2646\u20132663. https:\/\/doi.org\/10.1016\/j.ymthe.2022.06.004","journal-title":"Mol Ther"},{"key":"952_CR62","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","volume":"74","author":"BJ Samelson-Jones","year":"2023","unstructured":"Samelson-Jones BJ, George LA (2023) Adeno-associated virus gene therapy for hemophilia. Annu Rev Med 74:231\u2013247. https:\/\/doi.org\/10.1146\/annurev-med-043021-033013","journal-title":"Annu Rev Med"},{"issue":"14","key":"952_CR63","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.128683","volume":"4","author":"BJ Samelson-Jones","year":"2019","unstructured":"Samelson-Jones BJ, Finn JD, George LA, Camire RM, Arruda VR (2019) Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity. JCI Insight 4(14):e128683. https:\/\/doi.org\/10.1172\/jci.insight.128683","journal-title":"JCI Insight"},{"issue":"17","key":"952_CR64","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.1182\/bloodadvances.2023009876","volume":"7","author":"M Schmidt","year":"2023","unstructured":"Schmidt M, Foster GR, Coppens M et al (2023) Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B. Blood Adv 7(17):4966\u20134969. https:\/\/doi.org\/10.1182\/bloodadvances.2023009876","journal-title":"Blood Adv"},{"issue":"12","key":"952_CR65","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/14712598.2023.2282138","volume":"23","author":"T Sekayan","year":"2023","unstructured":"Sekayan T, Simmons DH, von Drygalski A (2023) Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency). Expert Opin Biol Ther 23(12):1173\u20131184. https:\/\/doi.org\/10.1080\/14712598.2023.2282138","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"952_CR66","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/03007995.2022.2133492","volume":"39","author":"J Shah","year":"2023","unstructured":"Shah J, Kim H, Sivamurthy K, Monahan PE, Fries M (2023) Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B. Curr Med Res Opin 39(2):227\u2013237. https:\/\/doi.org\/10.1080\/03007995.2022.2133492","journal-title":"Curr Med Res Opin"},{"key":"952_CR67","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.critrevonc.2015.12.009","volume":"99","author":"S Shetty","year":"2016","unstructured":"Shetty S, Sharma N, Ghosh K (2016) Epidemiology of hepatocellular carcinoma (HCC) in hemophilia. Crit Rev Oncol Hematol 99:129\u2013133. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.12.009","journal-title":"Crit Rev Oncol Hematol"},{"key":"952_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100759","volume":"47","author":"RF Sidonio","year":"2021","unstructured":"Sidonio RF, Pipe SW, Callaghan MU, Valentino LA, Monahan PE, Croteau SE (2021) Discussing investigational AAV gene therapy with hemophilia patients: a guide. Blood Rev 47:100759. https:\/\/doi.org\/10.1016\/j.blre.2020.100759","journal-title":"Blood Rev"},{"key":"952_CR69","doi-asserted-by":"crossref","unstructured":"Simioni P, Tormene D, Tognin G et al (2009) X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med. 361(17):1671\u20131675. https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa0904377. Accessed\u00a022 Oct 2009","DOI":"10.1056\/NEJMoa0904377"},{"issue":"13","key":"952_CR70","doi-asserted-by":"publisher","first-page":"10766","DOI":"10.3390\/ijms241310766","volume":"24","author":"AB Soroka","year":"2023","unstructured":"Soroka AB, Feoktistova SG, Mityaeva ON, Volchkov PY (2023) Gene therapy approaches for the treatment of hemophilia B. Int J Mol Sci 24(13):10766. https:\/\/doi.org\/10.3390\/ijms241310766","journal-title":"Int J Mol Sci"},{"issue":"1","key":"952_CR71","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1365-2516.2009.02127.x","volume":"16","author":"JS Stonebraker","year":"2010","unstructured":"Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I et al (2010) A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 16(1):20\u201332. https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02127.x","journal-title":"Haemophilia"},{"issue":"4","key":"952_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0243-1","volume":"51","author":"JJ Sung","year":"2019","unstructured":"Sung JJ, Park CY, Leem JW, Cho MS, Kim DW (2019) Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs. Exp Mol Med 51(4):1\u20139. https:\/\/doi.org\/10.1038\/s12276-019-0243-1","journal-title":"Exp Mol Med"},{"issue":"2","key":"952_CR73","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/hae.13668","volume":"25","author":"A Thalappillil","year":"2019","unstructured":"Thalappillil A, Ragni MV, Comer DM et al (2019) Incidence and risk factors for hepatocellular cancer in individuals with haemophilia: a National Inpatient Sample Study. Haemophilia 25(2):221\u2013228. https:\/\/doi.org\/10.1111\/hae.13668","journal-title":"Haemophilia"},{"issue":"2","key":"952_CR74","doi-asserted-by":"publisher","first-page":"263300402110588","DOI":"10.1177\/26330040211058896","volume":"24","author":"CD Thornburg","year":"2021","unstructured":"Thornburg CD (2021) Etranacogene dezaparvovec for hemophilia B gene therapy. Ther Adv Rare Dis 24(2):26330040211058896. https:\/\/doi.org\/10.1177\/26330040211058896","journal-title":"Ther Adv Rare Dis"},{"issue":"2","key":"952_CR75","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","volume":"69","author":"T Tsuchida","year":"2018","unstructured":"Tsuchida T, Lee YA, Fujiwara N et al (2018) A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol 69(2):385\u2013395. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.011","journal-title":"J Hepatol"},{"issue":"7","key":"952_CR76","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1073\/pnas.93.7.3056","volume":"93","author":"J Walter","year":"1996","unstructured":"Walter J, You Q, Hagstrom JN, Sands M, High KA (1996) Successful expression of human factor IX following repeat administration of adenoviral vector in mice. Proc Natl Acad Sci U S A 93(7):3056\u20133061. https:\/\/doi.org\/10.1073\/pnas.93.7.3056","journal-title":"Proc Natl Acad Sci U S A"},{"key":"952_CR77","unstructured":"World Federation of Hemophilia (2020) Report on the annual global survey 2020. WFH PhysicsWeb. https:\/\/www1.wfh.org\/publications\/files\/pdf-2045.pdf. Accessed 7 Feb 2022"},{"issue":"5","key":"952_CR78","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/hae.14607","volume":"28","author":"X Yang","year":"2022","unstructured":"Yang X, Jeong K, Yabes JG, Ragni MV (2022) Prevalence and risk factors for hepatocellular carcinoma in individuals with haemophilia in the era of direct-acting antiviral agents: a national inpatient sample study. Haemophilia 28(5):769\u2013775. https:\/\/doi.org\/10.1111\/hae.14607","journal-title":"Haemophilia"},{"issue":"10386","key":"952_CR79","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","volume":"401","author":"G Young","year":"2023","unstructured":"Young G, Srivastava A, Kavakli K et al (2023a) Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet Lond Engl 401(10386):1427\u20131437. https:\/\/doi.org\/10.1016\/S0140-6736(23)00284-2","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"952_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100179","volume":"7","author":"G Young","year":"2023","unstructured":"Young G, Lenting PJ, Croteau SE, Nolan B, Srivastava A (2023b) Antithrombin lowering in hemophilia: a closer look at fitusiran. Res Pract Thromb Haemost 7(4):100179. https:\/\/doi.org\/10.1016\/j.rpth.2023.100179","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"952_CR81","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1182\/blood.V110.11.196.196","volume":"110","author":"G Zhang","year":"2007","unstructured":"Zhang G, Shi Q, Fahs SA, Walsh CE, Montgomery RR (2007) Ectopic expression of human FIX in mouse platelets can store releasable FIX in platelets and may be a potential strategy for gene therapy of hemophilia B. Blood 110(11):196. https:\/\/doi.org\/10.1182\/blood.V110.11.196.196","journal-title":"Blood"}],"container-title":["Journal of Applied Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13353-025-00952-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13353-025-00952-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13353-025-00952-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T10:16:28Z","timestamp":1757153788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13353-025-00952-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["952"],"URL":"https:\/\/doi.org\/10.1007\/s13353-025-00952-w","relation":{},"ISSN":["1234-1983","2190-3883"],"issn-type":[{"value":"1234-1983","type":"print"},{"value":"2190-3883","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}